Peroxisome proliferator-activated receptor delta activation leads to increased transintestinal cholesterol efflux

Carlos L. J. Vrins, Astrid E. van der Velde, Karin van den Oever, Johannes H. M. Levels, Stephane Huet, Ronald P. J. Oude Elferink, Folkert Kuipers, and Albert K. Groen

Department of Medical Biochemistry, AMC Liver Center, and Department of Experimental Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands; Biology Department, GlaxoSmithKline, Les Ulis, France; and Center for Liver, Digestive, and Metabolic Diseases, University Medical Center Groningen, Groningen, The Netherlands

Abstract Peroxisome proliferator-activated receptor delta (PPARδ) is involved in regulation of energy homeostasis. Activation of PPARδ markedly increases fecal neutral sterol secretion, the last step in reverse cholesterol transport. This phenomenon can neither be explained by increased hepatobiliary cholesterol secretion, nor by reduced cholesterol absorption. To test the hypothesis that PPARδ activation leads to stimulation of transintestinal cholesterol efflux (TICE), we quantified it by intestine perfusions in FVB mice treated with PPARδ agonist GW610742. To exclude the effects on cholesterol absorption, mice were also treated with cholesterol absorption inhibitor ezetimibe or ezetimibe/GW610742. We found that treatment with PPARδ agonist GW610742 increased TICE, indicating that this pathway provides an interesting target for the development of drugs aiming at the prevention of atherosclerosis.

The peroxisome proliferator-activated receptor (PPAR) family belongs to the superfamily of nuclear receptors and consists of three known isoforms: PPARα, PPARβ/δ, and PPARγ (1). PPARα modulates various aspects of lipid metabolism (2–5) and is highly expressed in heart, liver, kidney, intestine, brown fat, i.e., organs that display high rates of fatty acid β-oxidation (6). PPARγ is expressed mainly in adipose tissue and affects adipocyte differentiation and energy metabolism, particularly the PPARγ2 isomer (7–10). PPARδ is ubiquitously expressed. High levels of PPARδ transcripts are detected in the brain, kidney, small intestine, and Sertoli cells (11). The role of PPARδ remained elusive for a long time until the successful generation of Pparδ−/− mice. Two groups independently created Pparδ−/− mouse lines (12, 13). Pparδ−/− mice were smaller from the fetal stage onwards and showed an increased prenatal death rate due to placental defects. Brain defects, limited adipose stores, and hyperplasia of the epidermis have been detected in these mice. PPARδ also plays a prominent role in fatty acid oxidation, energy dissipation, and mitochondrial respiration (14, 15). Adipose tissue-specific overexpression of PPARδ in mice protected these mice against high fat-induced obesity. In addition, db/db mice did not develop obesity upon treatment with a PPARδ agonist, GW501516 (15). Overexpression of PPARδ in skeletal muscle of mice led to a remarkable increase in energy endurance capacity (16). PPARδ activation of rat myotubes caused a prominent upregulation of mRNA coding proteins involved in intracellular cholesterol trafficking, which was increased upon PPARδ activation. Although treatment with ezetimibe alone had no effect on TICE, it reduced the effect of GW610742 on TICE. These data show that activation of PPARδ stimulates fecal cholesterol excretion in mice, primarily by the two-fold increase in TICE, indicating that this pathway provides an interesting target for the development of drugs aiming at the prevention of atherosclerosis.

Supplementary key words intestine • transintestinal cholesterol efflux • reverse cholesterol transport

Abbreviations: Apo, apolipoprotein; HPGC, high performance gel-filtration chromatography; HPRT, hypoxanthine-guanine phosphoribosyl transferase; Ldlr−/−, Ldl receptor knockout; NPC1L1, Niemann-Pick C1-like 1; PC, phosphatidylcholine; PPAR, peroxisome proliferator-activated receptor; RCT, reverse cholesterol transport; TC, taurocholate; TICE, transintestinal cholesterol transport.

This study was supported by grant 04-55 from the Dutch Digestive Foundation (MDLS), grant 912-02-063 from the Netherlands Organization for Scientific Research (NWO), and grant T2-110 from TI-Pharma.

Manuscript received 7 November 2008 and in revised form 19 February 2009 and in revised form 12 May 2009.

Published, JLR Papers in Press, May 13, 2009

DOI 10.1194/jlr.M800579-JLR200

Copyright © 2009 by the American Society for Biochemistry and Molecular Biology, Inc.

This article is available online at http://www.jlr.org

To whom correspondence should be addressed.
e-mail: vrins@amc.uva.nl
levels of pyruvate dehydrogenase kinase 4 (PDK4). Treatment with a PPARδ agonist also improved insulin resistance induced by a high-fat diet in mice (14). So, apparently, PPARδ couples fatty acid metabolism with glucose metabolism. Takahashi et al. (17) suggested that the physiological role of PPARδ may be a direct switch from glucose metabolism to fatty acid metabolism.

Besides the roles of PPARδ in fatty acid and glucose homeostasis, PPARδ activation is also suggested to affect reverse cholesterol transport (RCT). PPARδ activation leads to increased levels of HDL cholesterol in primates and humans and enhanced apolipoprotein (Apo)A-I specific cho-

to increased levels of HDL cholesterol in primates and hu-

巢 sterol efflux from THP1 human monocyte cells (18, 19). Van der Veen et al. (20) showed that PPAR activation resulted in increased fecal neutral sterol output, whereas hepato-

patal cholesterol secretion was unaltered. PPARδ activation in wild-type DBA1 mice led to reduced choles-

terol absorption efficiencies. This reduced absorption seemed to be caused by the attenuated expression of the gene encoding the Niemann-Pick C1-like 1 protein (NPC1L1) that mediates cholesterol absorption (21). Although cholesterol absorption was reduced, it could not fully explain the increase in fecal neutral sterol secretion. Recently, our group showed that direct transintestinal cholesterol efflux (TICE) represents a major pathway for the excretion of cholesterol in mice (22). Because PPARδ activation led to an increase in fecal neutral sterol secretion that could not be accounted for by an increase in hepato-

patal cholesterol secretion nor solely by reduction of cholesterol absorption, we hypothesized that PPARδ activa-

tion leads to stimulation of TICE.

MATERIALS AND METHODS

Animals and diet

Male FVB mice (2–4 months) were purchased from Harlan (Horst, The Netherlands). Mice ( n = 7 for each group) received a reference diet (20% casein, ref no 4068.02, Arie Blok BV, The Netherlands), a diet containing PPARδ agonist with 0.1 ml FFD [Hypnorm (fentanyl/fluanisone; 1 ml/kg) and diazepam (10 mg/kg)] / 5 g body weight and placed on a heat pad to maintain body temperature. The bile duct was cannulated via the gallbladder to divert biliary cholesterol. Bile flow was determined gravimetrically assuming a density of 1 g/ml. The first 15 min fraction was used to measure biliary cholesterol secretion. Proximal small intestines (first 10 cm) were perfused because, under normal conditions, the highest TICE rate is observed in the proximal part of the small intestine (22). Perfusions were performed as previously described (22). Perfusate fractions were stored at −20°C until further analysis. At the end of the perfusion period, blood was collected by cardiac puncture and plasma was obtained by means of centrifugation (3000 rpm, 5 min). Plasma was stored at −80°C. The perfused intestinal segment was cut into three equal pieces and those pieces were cut in two equal parts. The intestinal segments were snap-frozen in liquid nitrogen. Intestinal segments and plasma were stored at −80°C before further analysis.

Perfusion fluid composition

Perfusates were carried out with a modified Krebs solution (119.95 mM NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4·7H2O, 15 mM HEPES, 1.5 mM CaCl2·2H2O, and 10 mM L-glutamine; final pH 7.4) supplemented with 10 mM tauro-

cholate (TC; Sigma, Zwijndrecht, The Netherlands): 2 mM L-α-

-phosphatidylcholine (PC; Sigma). TC/PC mixtures were made as follows: TC dissolved in methanol and egg yolk and PC dis-

TABLE 1. Real-time PCR primers

| Gene  | Accession Number | Forward Primer | Reverse Primer | Size (bp) |
|-------|-----------------|----------------|----------------|----------|
| 36B4  | NM_007475       | GACGCCGAGAAGACCTCCTT | GCACATCATCAGATTTCAATGTG | 85 |
| ABCA1 | NM_013454       | GCTTGGAGAATGTTTCTTCAATATGTTT | TCCCGGGAAGTTGGTCATG | 96 |
| ABCG5 | NM_018884       | TGGGCCCTGTCGACATC | ATTTTAAAAGAATGGGATGCTTCTT | 81 |
| ABCG8 | NM_026180       | CGGTCGTCGATATTCCCAATGA | GGTTCGCCACCATGGAAG | 67 |
| Cyclophilin | M60456 | TGGAGCGCAATATGAAAGGT | AAAAGGAGAGAGGCGGAC | 65 |
| HMG-CoA Reductase | M62766 | TCTGGGCTTCTGCTGGAATATT | CCTGCTCCTGCGTCAATTT | 69 |
| HPRT  | J00423          | TGGCTGCAAGATGTCATGGAGGA | AGCAGGTCAGCAAAGAAGTCATAG | 91 |
| NPC1L1| AY937866        | AGAAGCCGGGAAAGTCTACTATATCCTCA | CCCGGGAAAGTTGTCATG | 72 |
| Pdk4  | NM_013743       | CGGGGGAGCAGCTGAGATTT | CAGGAGTTACAGGGCCACC | 191 |
| SCD-1 | NM_009127       | TACTACAGCCGCGCCTC | CAGGAGTTACAGGGGACCAA | 65 |
| SR-B1 | NM_016741       | GCGTCTGTTTCTCTGGCC | GCTGCTGCTGAGGGAGGG | 63 |
| LIMP2 (SR-BII) | NM_007644 | AGAGCCGGGATAGGACAGAC | GTAGGGGGATTTCTCTTGGA | 159 |
| Rab9  | NM_019773       | TACGCCAGATGTGAAAGGCT | AAAGTAAAGATGTCGGTGTG | 132 |

PPARδ affects the transintestinal cholesterol efflux 2047
solved in chloroform were mixed and solvents were evaporated under a mild stream of nitrogen at 45°C. After evaporation, films were lyophilized overnight. Lyophilized samples were stored under nitrogen gas at -20°C until the day of the intestine perfusions. Before the start of the intestine perfusions, the micelles were dissolved in perfusion buffer (room temperature).

**Determination of mRNA levels**

Total RNA was isolated from perfused intestinal segments using the Trizol reagent according to the manufacturer’s protocol (Invitrogen, Breda, The Netherlands). Purified RNA was treated with RQ1 RNase-free DNase (1 unit/2 µg of total RNA; Promega, Leiden, The Netherlands) and reverse transcribed with Super-Script II Reverse Transcriptase (Invitrogen,) according to the protocols supplied by the manufacturer. Gene expression analysis was performed by use of SYBR green. Quantitative gene expression analysis was performed on a Bio-Rad MyQ Single-Color Real-Time PCR Detection System (Bio-Rad, Veenendaal, The Netherlands). PCR primers were designed on the basis of PrimerBank website (http://pga.mgh.harvard.edu/primerbank) or found by consulting the PrimerExpress 1.7 software with the manufacturer's default settings (Applied Biosystems, Foster City, CA) and validated for identical efficiencies (Table 1). Hypoxanthine-guanine phosphoribosyl transferase (HPRT), cyclophilin, and acidic ribosomal phosphoprotein P0 (36B4) were used as standard housekeeping genes.

**Lipoprotein analysis**

Total cholesterol content of the main lipoprotein classes, VLDL, LDL, and HDL, was determined using high performance gel-filtration chromatography (HPGC) as described previously with some minor modifications (23). In brief, the system contained a PU-5000 ternary pump with an LG-9800-02 linear degasser, FP-920 fluorescence and UV-975 UV/VIS detectors (Jasco, Tokyo, Japan). An extra PU1500 pump (Jasco) was used for in-line cholesterol PAP enzymatic reagent (Biomerieux, Marcy l’Etoile, France) addition (flowrate; 0.1 ml/min). Plasma lipoprotein separations were performed with a Superose 6 HR 10/30 column (Pharmacia Biotech, Uppsala, Sweden) with TBS pH 7.4 as eluent (flow rate; 0.31 ml/min). Plasma lipoprotein fractions were obtained by averaging the data of the last three perfusion time points. Differences between different groups were determined by one-way ANOVA. Outcomes of P < 0.05 were considered to be significant. Analysis was performed using SPSS.

**Apolipoprotein composition analysis of plasma lipoproteins**

For analysis of apolipoproteins, pooled plasma samples from control and GW610742-treated animals were fractionated by the aforementioned HPGC (flowrate 0.5 ml/min; fractions collected at a 1-min interval). The lipoprotein profile spanned the fractions 3–19. Equal volumes (20 µl) of these fractions were separated on 4–12% gradient gels (Invitrogen, Carlsbad, CA) and the proteins were transferred to nitrocellulose membranes (Protran BA, Whatman, Germany). The blots were blocked in Starting Block buffer (Pierce, Rockford, IL) and probed with rabbit anti-mouse ApoB and ApoA1 (prepared at TNO-Biosciences; kind gift from Jitske de Vries-Van der Weij), and goat anti-mouse ApoE (Santa Cruz, Heerhugowaard, The Netherlands; sc-6384) in block buffer containing 0.05% (v/v) Tween-20, overnight at 4°C. Blots were washed for 50 min in TBS (10 mM Tris-HCl (pH 8.0), 150 mM NaCl) containing 0.01% (v/v) Tween-20. Proteins were detected with an infrared fluorescence detection system and secondary antibodies (Odyssey and IRDye 680 antibody, LI-COR Biosciences, Germany).

**Analytical procedures**

Lipids of perfusate and bile were extracted using the Bligh and Dyer method (24). Biliary, perfusate, and hepatic cholesterol were measured by a fluorescent method as described previously (25). Total cholesterol concentrations of complete plasma samples were determined using the cholesterol RTU kit from Biomerieux. Triglycerides in plasma and liver homogenates were determined using the Triglycerides Ecoline S+ kit (Diagnostic Systems GmbH, Holzheim, Germany). Biliary and hepatic phospholipids were measured enzymatically by a method described previously (26). Bile acids in bile were measured by a method described earlier by Turley and Dietschy (27). For fecal neutral sterol analysis, 1 day fecal samples were collected, lyophilized, and ground. Samples were prepared for fecal neutral sterol analysis by gas chromatography as described previously (28).

**Statistics**

All results are presented as mean ± SD. Group means for TICE, as depicted in the figures, were calculated by averaging the outcomes of all mice that got the same treatment. The values for the individual mice, used for the calculation of the group mean, were obtained by averaging the data of the last three perfusion time points. Differences between different groups were determined by one-way ANOVA. Outcomes of P < 0.05 were considered to be significant. Analysis was performed using SPSS.

---

**TABLE 2.** Effect of GW610742 on fecal neutral sterol excretion and food intake

|                | Ref. Diet | GW610742 | Ezetimibe | Ezetimibe + GW610742 |
|----------------|-----------|-----------|-----------|----------------------|
| Fecal neutral sterol secretion (µmol/day.100g) | 6.6 ± 0.5 | 18.0 ± 1.2* | 40.9 ± 6.5* | 48.0 ± 3.4          |
| Food intake (g/day.100g) | 15.0 ± 2.4 | 26.1 ± 4.5* | 16.1 ± 1.8 | 15.6 ± 0.9          |

*Indicates a significant effect of GW610742 in comparison to control treated animals.

---

**Fig. 1.** Effect of GW610742 treatment on intestinal cholesterol efflux. FVB mice (n = 7 per group) received casein diet, a GW610742 diet (0.017% w/w), an ezetimibe diet (10 mg/kg/day), or an ezetimibe + GW610742 diet for 2 weeks. Proximal small intestinal perfusions were performed, using TC/PC (10:2 mM) as cholesterol acceptor. Values are expressed as means ± SD. * indicates a significant effect of GW610742 in comparison to control treated animals.
RESULTS

To establish the effect of PPAR\(\delta\) activation on cholesterol metabolism, four groups of FVB mice received either a semi-purified reference diet, or the same diet supplemented with ezetimibe, or the PPAR\(\delta\) agonist GW610742, or both ezetimibe and GW610742. Mice were given these diets for 2 weeks. After the first week, food intake and fecal neutral sterol output were measured and after the second week, the proximal small intestine was perfused to quantify TICE. Table 2 shows that GW610742 treatment stimulated fecal neutral sterol excretion. Food intake was monitored during the same period as fecal neutral sterol excretion was measured. Surprisingly, the GW610742 treated mice ate 1.7-fold more than control mice did. Interestingly, this effect was abolished in the presence of ezetimibe.

PPAR\(\delta\) activation by GW610742 treatment stimulated TICE significantly (Fig. 1) (2.39 ± 0.56 versus 1.37 ± 0.53 nmol cholesterol/min.100 g body wt, \(P < 0.05\)). In combination with ezetimibe, the stimulatory effect of GW610742 on TICE was not significant (1.64 ± 0.80 versus 1.12 ± 0.34 nmol cholesterol/min.100 g body wt). Interestingly, ezetimibe alone did not affect TICE in FVB mice.

As reported earlier, GW610742 treatment caused an increase (50% to 60%) in liver weight as compared with the liver weights of the corresponding control mice (Table 3) (20, 29). This increase was not caused by the accumulation of lipids because cholesterol, phospholipids, and triglyceride levels did not change when expressed per mg liver protein (20). GW610742 treatment led to a significant increase in bile flow and bile salt secretion rate but had no effect on biliary cholesterol secretion or phospholipid secretion (Table 4). Ezetimibe alone also induced bile salt secretion but displayed no synergistic effect when given with GW610742.

Total plasma cholesterol and triglyceride levels did not change upon GW610742 treatment (Fig. 2A, B). To evaluate whether GW610742 treatment resulted in changes in cholesterol concentrations in the different lipoproteins, HPGC was performed (Fig. 2C). In addition, the apolipoprotein composition of lipoproteins in the plasma of the GW610742 treated and the nontreated mice was determined (Fig. 2D). After fractionating the plasma samples, the presence of ApoA1, ApoB, and ApoE was visualized by Western blotting. GW610742 induced a shift of cholesterol from HDL toward the ApoB-containing LDL-fraction.

Intestinal gene expression analysis was performed to establish the role of PPAR\(\delta\) activation on the expression of genes that are involved in cholesterol transport as well as known PPAR\(\delta\) target genes (Fig. 3). The classic PPAR\(\delta\) target Pdk4 was induced about 10-fold whereas steroyl-CoA desaturase 1 expression was induced even more, about 20-fold. The expression of the cholesterol efflux protein Abca1 was increased and Npc1l1 expression was reduced upon PPAR\(\delta\) activation, as described previously (20). Sr-b1 expression was not altered upon GW610742 treatment, but ezetimibe significantly decreased Sr-b1 expression. Abcg5, Abcg8, and Hmg-CoA reductase were not affected by GW610742, nor did ezetimibe affect the expression of these genes. Because the NPC1L1 mediated cholesterol transport involves intracellular vesicle trafficking (30), we also determined expression of genes known to be involved in this pathway (31, 32). Interestingly, expression of Rab9 and Limp-2 was increased upon GW610742 treatment.

DISCUSSION

In this study, we show for the first time that increased fecal neutral sterol output in FVB mice upon PPAR\(\delta\) activation by GW610742 is largely due to stimulation of TICE. In an earlier study, Van der Veen et al. (20) demonstrated that treatment of DBA1 mice with GW610742 decreased expression of Npc1l1, contributing to the observed increase in fecal neutral sterol excretion. To control for the influence of NPC1L1, we tested the effect of GW610742

| TABLE 3. Liver parameters |
|---------------------------|
|                          |
| Ref. Diet                 | GW610742 | Ezetimibe | Ezetimibe+ GW610742 |
| Liver weight (\% of body weight) | 4.5 ± 0.2 | 6.7 ± 0.4* | 4.3 ± 0.4 | 6.7 ± 0.4* |
| Hepatic triglycerides (nmol/mg liver) | 9.4 ± 6.2 | 5.2 ± 2.7 | 13.6 ± 5.1 | 8.0 ± 4.4 |
| Hepatic cholesterol (nmol/mg liver) | 7.5 ± 0.7 | 6.1 ± 2.2 | 7.8 ± 1.3 | 7.1 ± 1.9 |
| Hepatic phospholipids (nmol/mg liver) | 24.5 ± 3.0 | 24.4 ± 8.6 | 23.7 ± 2.3 | 29.3 ± 5.5 |

Values are expressed as means ± SD.

* Indicates a significant difference between the GW610742 treated animals and their corresponding controls.

| TABLE 4. Bile flow and secretion rates |
|---------------------------------------|
|                                      |
| Ref. Diet                           | GW610742 | Ezetimibe | Ezetimibe+ GW610742 |
| Bile flow (µl/min.g liver)          | 0.9 ± 0.6 | 2.7 ± 0.6* | 1.3 ± 0.5 | 2.6 ± 0.8* |
| Bile salts (nmol/min.100g body wt)  | 69 ± 28   | 163 ± 79* | 191 ± 74 | 132 ± 79* |
| Cholesterol (nmol/min.100g body wt) | 0.9 ± 0.3 | 0.8 ± 0.4 | 0.9 ± 0.3 | 0.5 ± 0.2* |
| Phospholipids (nmol/min.100g body wt) | 8.3 ± 1.3 | 8.7 ± 4.4 | 12.2 ± 3.9 | 7.7 ± 4.0 |
| Cholesterol / phospholipids ratio    | 0.11 ± 0.02 | 0.10 ± 0.04 | 0.08 ± 0.01 | 0.07 ± 0.02 |

Values are expressed as means ± SD.

* Indicates a significant difference between the GW610742 treated animals and their corresponding controls.
Fig. 2. Plasma analysis of GW610742 treated mice. FVB mice (n = 7 per group) received casein diet, a GW610742 diet (20 mg/kg/day), an ezetimibe diet (10 mg/kg/day) or an ezetimibe + GW610742 diet for 2 weeks. Blood was collected and plasma was obtained by centrifugation. A: Total plasma cholesterol levels and (B) plasma triglyceride levels were measured. C: Lipoproteins were separated by HPGC combined with subsequent in-line total cholesterol determination. D: Fractions obtained by HPGC were subjected to Western blot. Via detection of ApoA1, ApoB, and ApoE, the apolipoprotein composition of the lipoprotein profiles was determined.
PPARδ affects the transintestinal cholesterol efflux.
with and without ezetimibe, an established inhibitor of NPC1L1. As shown previously, treatment of mice with ezetimibe alone has a substantial effect on neutral sterol excretion (33). Part can be explained by inhibition of cholesterol absorption, but because biliary cholesterol secretion is not affected, the question arises, from where this cholesterol originates. However, despite the strong increase of fecal neutral sterol excretion, ezetimibe treatment did not affect TICE. On the one hand, this result shows that NPC1L1 does not play an (inhibiting) role in TICE. On the other hand, TICE is not involved in the ezetimibe-induced strong increase in neutral fecal sterol excretion and another pathway must be responsible. In contrast to the effect of ezetimibe, treatment of the mice with GW610742 alone stimulated TICE, which subsequently contributed to the increase of fecal neutral sterol excretion. Because ezetimibe has no effect on TICE, similar results were expected upon concurrent treatment with GW610742. However, GW610742 treatment in the presence of ezetimibe showed no significant increase of TICE. It could be that ezetimibe interferes with intestinal uptake of GW610742 but also a possible intervention of ezetimibe on the PPARα-activated pathways cannot be ruled out.

GW610742-treated animals ate significantly more than control animals although they did not differ in body weight (not shown). An increased food consumption has also been observed in Ldlr receptor knockout (Ldlr\(^{-/-}\)) mice treated with PPARα agonist GW610742 (34). In that study, however, the GW610742-treated Ldlr\(^{-/-}\) mice showed a significant increase in body weight as compared with Ldlr\(^{-/-}\) mice on a control diet. Muscle-specific PPARα transgenic animals had enhanced physical activity, however, they did not differ in body weight as compared with wild-type mice (16). An effect of PPARα activation on energy expenditure might explain why GW610742-treated mice were able to maintain body weight with increased food intake. Surprisingly, the stimulating effect of PPARα activation by GW610742 treatment on food consumption was not observed when ezetimibe was given at the same time. The recently reported inhibitory effect of ezetimibe on absorption of fatty acids (35) may play a role although we can also not exclude that ezetimibe might attenuate the uptake of GW610742. Additionally, treatment with GW610742 caused an increase in liver weight, which has been reported before and was not caused by accumulation of liver lipids (20). A recent report attributed this induction in liver weight to peroxisome proliferation (29).

PPARα activation led to a higher bile flow and a higher bile salt secretion rate both with and without ezetimibe treatment (Table 3). This has not been observed previously in DBA1 wild-type mice (20). Cholesterol and other biliary parameters were unaffected upon GW610742 treatment, as observed in DBA1 (20). In addition, total plasma cholesterol and triglycerides levels were unaltered upon PPARα activation (Fig. 2A) as has been observed previously in Ldlr\(^{-/-}\) mice treated with GW610742 (34). In fact, GW610742 treatment in Ldlr\(^{-/-}\) mice did not affect plasma lipoprotein profiles. Subsequent cholesterol and apolipoprotein analyses of the lipoprotein profiles in FVB mice revealed a shift from HDL to LDL in both GW610742-treated groups. In contrast, earlier studies in monkeys and humans reported increased HDL cholesterol levels upon PPARα activation (18, 19). Also in DBA1 mice, PPARα activation resulted in higher HDL levels (20). Whether our observed change in lipoprotein profiles in FVB mice reflects a strain-specific difference and whether this change in plasma cholesterol distribution might affect TICE need to be investigated.

To get more insight in genes potentially involved in up-regulation of TICE, analysis of intestinal gene expression was performed (Fig. 3). Confirming earlier results, the expression of Npc1l1 was decreased in GW610742-treated mice (20). Conversely, expression of Abca1 was increased whereas that of Sr-b1 was not affected. Expression of the cholesterol effluxing heterodimer Abcg5/g8 was not influenced. This came as no surprise because we have shown previously that these genes do not control the rate of TICE under the conditions used in this study (22). Ezetimibe treatment decreased the effect of GW610742 on its known target gene Pdk4, suggesting that indeed ezetimibe influences uptake of the agonist. To further investigate the underlying mechanism of PPARα-induced TICE activation, we also studied the effect of GW610742 treatment on expression of genes that have been linked to the intracellular vesicular transport of cholesterol, namely, Rab8, Rab9, and LIMP-II. Rab8 is involved in the regulatory machinery that leads to ABCA1-dependent removal of cholesterol from endocytic circuits (31). Rab9 plays a role in cholesterol trafficking from late endosomes to the trans-Golgi network (32, 36). Also LIMP-II, previously referred to as LPG58, has specific functions in intracellular vesicular trafficking (37). Interestingly, LIMP-II is the mouse ortholog of human scavenger receptor class B type 2 (Scarb2; MIM* 602257) which has been shown to influence cholesterol homeostasis (38). Intestinal Rab8 expression was unaltered upon PPARα activation (data not shown). In contrast, expression of Rab9 and Limp-II was increased significantly. How the proteins encoded by these genes are related to TICE is not yet clear and requires further study.

In earlier studies, PPARα activation has been shown to increase fecal sterol secretion without affecting the rate of biliary cholesterol secretion (20). The positive effect of PPARα on cholesterol secretion, which suggests an

---

**Fig. 3.** Intestinal gene expression analysis of GW610742 treated mice. FVB mice (n = 7 per group) received casein diet, a GW610742 diet (20 mg/kg/day), an ezetimibe diet (10 mg/kg/day) or an ezetimibe + GW610742 diet for 2 weeks. Proximal small intestinal perfusions were performed, using TC/PC (10:2 mM) as cholesterol acceptor. At the end of the 2-h perfusion period, intestines were collected cut into three equal segments. The middle segment was analyzed. As control genes cyclophilin, 36B4 and HPRT were used. Values are expressed as means ± SD. * indicates a significant effect of GW610742 in comparison to control treated animals.
accelerated RCT, is not confined to mice but has also been demonstrated to occur in primates and humans (18, 19). Here, we show that the effect of PPARβ on neutral sterol excretion is in part mediated by stimulation of TICE. This effect is in line with the stimulatory effect of a high-fat diet on TICE described recently (39). Activation of PPARβ by fatty acid influx into enterocytes may induce TICE. Given the role of RCT in atherosclerosis, we speculate that TICE may be a promising target for the development of novel drugs to prevent or treat cardiovascular diseases.

REFERENCES

1. Lemberger, T., B. Desvergne, and W. Wahli. 1996. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. *Annu. Rev. Cell Dev. Biol.* 12: 353–363.

2. Dreyer, C., G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli. 1992. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. *Cell* 68: 879–887.

3. Ciriaco, T., S. Mosci, T. Caira, D. P. Kelly. 1994. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. *Proc. Natl. Acad. Sci. USA* 91: 11012–11016.

4. Rodriguez, J. C., G. Gil-Gomez, F. G. Hegardt, and D. Haro. 1994. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. *J. Biol. Chem.* 269: 18767–18772.

5. Tugwood, J. D., I. Issemann, R. G. Anderson, K. R. Bundell, W. L. McPheat, and S. Green. 1992. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. *EMBO J.* 11: 433–439.

6. Issemann, I., and S. Green. 1991. Cloning of novel members of the steroid hormone receptor superfamily. *J. Steroid Biochem.* Mol. Biol. 40: 263–269.

7. Graves, R. A., P. Tontonoz, and B. M. Spiegelman. 1992. Analysis of a tissue-specific enhancer: ARF6 regulates adipogenic gene expression. *Mol. Cell. Biol.* 12: 3513.

8. Erranz, B., J. F. Miquel, W. S. Argraves, J. L. Barth, F. Pimentel, and M. P. Marzolo. 2004. Megalin and cubulin expression in gallbladder epithelium and regulation by bile acids. *J. Lipid Res.* 45: 2185–2198.

9. Tontonoz, P., E. Hu, J. Devine, E. G. Beale, and B. M. Spiegelman. 1995. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. *Mol. Cell. Biol.* 15: 351–357.

10. Braissant, O., F. Foulfelle, C. Scotto, M. Dauca, and W. Wahli. 1996. Differential expression of peroxisome proliferator-activated receptor (PPARs): tissue distribution of PPAR-alpha, beta, and gamma in the adult rat. *Endocrinology* 137: 354–366.

11. Amri, E. Z., F. Bonino, G. Alilhoud, N. A. Abumrad, and P. A. Grimaldi. 1995. Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors. *J. Biol. Chem.* 270: 2567–2571.

12. Barak, Y., D. Liao, W. He, E. S. Ong, M. C. Nelson, J. M. Olefsky, R. Bolond, and R. M. Evans. 2002. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. *Proc. Natl. Acad. Sci. USA* 99: 303–308.

13. Peters, J. M., S. S. Lee, W. Li, J. M. Ward, O. Gavrilova, C. Everett, M. L. Reitman, L. D. Hudson, and F. J. Gonzalez. 2000. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). *Mol. Cell. Biol.* 20: 5119–5128.

14. Tanaka, T., Y. Yamamoto, S. Iwasaki, H. Asaha, H. Hamura, Y. Ikeda, M. Watanabe, K. Magoori, R. X. Ioka, K. Tachibana, et al. 2003. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. *Proc. Natl. Acad. Sci. USA* 100: 15924–15929.

15. Wang, Y., X. C. Lee, S. Tiep, R. T. Yu, J. Ham, H. Kang, and R. M. Evans. 2003. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. *Cell* 113: 159–170.

16. Wang, Y., X. C. Zhang, R. T. Yu, H. K. Cho, M. C. Nelson, C. R. Bayuaga-Ocampo, J. Ham, H. Kang, and R. M. Evans. 2004. Regulation of muscle fiber type and running endurance by PPARdelta. *PLoS Biol.* 2: e94.
36. Choudhury, A., M. Dominguez, V. Puri, D. K. Sharma, K. Narita, C. L. Wheatley, D. L. Marks, and R. E. Pagano. 2002. Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells. *J. Clin. Invest.* 109: 1541–1550.

37. Eskelinen, E. L., Y. Tanaka, and P. Saftig. 2003. At the acidic edge: emerging functions for lysosomal membrane proteins. *Trends Cell Biol.* 13: 137–145.

38. Eckhardt, E. R., L. Cai, B. Sun, N. R. Webb, and D. R. van der Westhuizen. 2004. High density lipoprotein uptake by scavenger receptor SR-BII. *J. Biol. Chem.* 279: 14372–14381.

39. van der Velde, A. E., C. L. Vrins, K. van den Oever, I. Seemann, R. P. Oude Elferink, M. van Eck, F. Kuipers, and A. K. Groen. 2008. Regulation of direct transintestinal cholesterol excretion in mice. *Am. J. Physiol. Gastrointest. Liver Physiol.* 295: G203–G208.